If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epithalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
GIP / GLP-1 / glucagon tri-agonist
Supply and ordering
For a metabolic-peptide sourcing program, compare Retatrutide availability, fill sizes, and order timing with Tirzepatide, Mazdutide, Survodutide, and Semaglutide.
Overview
Retatrutide (Eli Lilly development code LY3437943) is a 39-amino-acid investigational tri-agonist peptide targeting the GIP, GLP-1, and glucagon receptors. The glucagon-receptor component differentiates Retatrutide from the dual-agonist class (Tirzepatide, Mazdutide, Survodutide) by adding direct hepatic-energy-expenditure modulation on top of the incretin-driven glycemic and weight effects, which is the mechanistic basis for the larger weight-reduction signals observed in Phase 2 trials versus prior best-in-class agents. PeptideXpo supplies lyophilized Retatrutide acetate to a ≥99.0% HPLC purity specification with a batch COA covering peak-integration HPLC purity and ESI mass spec for identity; water content and counter-ion are available on request and listed on the COA when tested. Bacterial endotoxin (LAL, USP <85>) and microbial limits (USP <61>/<62>) are available as add-on testing for in vivo workflows and 503A / 503B compounding pharmacy use. Eight standard fill sizes (5 mg through 60 mg) cover both research aliquot scales and dispensing-vial workflows. Bulk pricing tightens significantly at the 100 g and 1 kg break points, Retatrutide aggregate production volumes are lower than for Semaglutide / Tirzepatide, so the per-mg cost curve is steeper but stabilizes once a recurring synthesis route is locked.
Who buys this, and why
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Also available as a nasal spray (US stock)
Besides lyophilized vials, Retatrutide is stocked in the US as a ready-to-use nasal spray.
Capsules · US stock
Retatrutide is also supplied as capsules from our US stock.
Documentation available on request
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COARetatrutide 5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 10 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 15 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 20 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 30 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 40 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 50 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 60 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 100 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Third-party reportRetatrutide 50 mg
HPLC purity · MS identity
Third-party laboratory, Tianjin, China
Full, clear copy from sales
Customer-shared reportRetatrutide 20 mg
Purity · Content per vial
Janoshik (independent laboratory)
Full, clear copy from sales
Customer-shared reportRetatrutide 60 mg
Purity · Content per vial
Janoshik (independent laboratory)
Full, clear copy from sales
Independent test fails? Full refund. How it works
Regulatory note
Investigational compound currently in clinical development; not approved as a finished drug in any jurisdiction. Sold as a bulk active for research and, in markets where regulations permit, for compounding-pharmacy use under the receiving pharmacy's quality system. Buyers are responsible for verifying compounding eligibility against the destination market's current regulatory posture.
Selected literature
Frequently asked questions
Tirzepatide is a dual GIP / GLP-1 agonist; Retatrutide adds glucagon-receptor agonism for tri-mechanism activity. The glucagon arm contributes hepatic-energy-expenditure effects that are absent from the dual-agonist class, the practical readout in Phase 2 has been larger weight-reduction magnitudes than any prior peptide in the metabolic space, including Tirzepatide at comparable exposure ranges. Sequence-wise both are 39-amino-acid peptides with C20 fatty-diacid lipidation, but the receptor-binding determinants and the fatty-acid linker geometry differ.
Retatrutide is still investigational, so commercial-pharmacy compounding in most jurisdictions is constrained to the same shortage / regulatory considerations that apply to other unapproved actives. Most current Retatrutide volume goes to: (1) pre-clinical and translational research labs studying tri-agonist receptor pharmacology, (2) compounding pharmacies in markets with permissive frameworks for investigational-stage actives, and (3) regulated buyers building IND-track or analogous documentation packages. All three need batch-specific COA depth, and PeptideXpo can supply the underlying chromatograms and mass-spec raw data files as COA attachments for documentation-track buyers.
Aggregate production volume drives unit cost on synthetic peptides in this class, and Retatrutide volumes are still a small fraction of Tirzepatide / Semaglutide. The synthesis itself is more demanding (longer SPPS sequence with tighter purification cycles to clear closely-eluting deletion sequences). Pricing improves materially at the 100 g and 1 kg break points and tightens further on repeat orders against a locked synthesis route, first-quote economics are not representative of recurring-order economics.
Yes. Retatrutide is also stocked as a ready-to-use nasal spray (5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg) in 10 mL or 20 mL bottles, from 10 bottles of each. These orders ship from our US stock; ask our sales team for details and a quote.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
